Castleark Management LLC Has $8.74 Million Holdings in Kiniksa Pharmaceuticals International, plc $KNSA

Castleark Management LLC lessened its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 5.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 181,512 shares of the company’s stock after selling 10,680 shares during the period. Castleark Management LLC owned about 0.24% of Kiniksa Pharmaceuticals International worth $8,740,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. raised its position in Kiniksa Pharmaceuticals International by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock valued at $128,409,000 after buying an additional 49,802 shares during the last quarter. UBS Group AG lifted its stake in Kiniksa Pharmaceuticals International by 56.4% in the 4th quarter. UBS Group AG now owns 77,916 shares of the company’s stock valued at $3,214,000 after acquiring an additional 28,099 shares in the last quarter. Aberdeen Group plc boosted its position in Kiniksa Pharmaceuticals International by 152.4% during the 4th quarter. Aberdeen Group plc now owns 400,598 shares of the company’s stock worth $16,525,000 after acquiring an additional 241,876 shares during the last quarter. BNP Paribas Financial Markets boosted its position in Kiniksa Pharmaceuticals International by 27.3% during the 4th quarter. BNP Paribas Financial Markets now owns 831,777 shares of the company’s stock worth $34,311,000 after acquiring an additional 178,366 shares during the last quarter. Finally, Inspire Investing LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $1,698,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, CEO Sanj K. Patel sold 483,654 shares of the company’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $51.86, for a total transaction of $25,082,296.44. Following the sale, the chief executive officer directly owned 431,904 shares of the company’s stock, valued at approximately $22,398,541.44. This represents a 52.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry D. Quart sold 13,099 shares of the stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $50.10, for a total transaction of $656,259.90. Following the completion of the sale, the director owned 12,546 shares of the company’s stock, valued at approximately $628,554.60. This represents a 51.08% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 628,427 shares of company stock worth $32,833,228. Insiders own 51.98% of the company’s stock.

Kiniksa Pharmaceuticals International Price Performance

KNSA stock opened at $62.84 on Monday. The business has a 50 day moving average price of $56.87 and a two-hundred day moving average price of $50.03. The company has a market cap of $4.83 billion, a price-to-earnings ratio of 69.82 and a beta of 0.07. Kiniksa Pharmaceuticals International, plc has a twelve month low of $26.27 and a twelve month high of $67.53.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The firm had revenue of $214.27 million for the quarter, compared to analyst estimates of $206.11 million. During the same quarter in the previous year, the firm earned $0.11 EPS. The business’s quarterly revenue was up 55.5% on a year-over-year basis. On average, equities research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.25 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on KNSA shares. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 12th. Weiss Ratings cut shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 23rd. Citigroup raised their target price on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. The Goldman Sachs Group raised their target price on shares of Kiniksa Pharmaceuticals International from $60.00 to $75.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Wedbush boosted their price target on shares of Kiniksa Pharmaceuticals International from $59.00 to $72.00 and gave the stock an “outperform” rating in a research report on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has an average rating of “Buy” and an average price target of $68.00.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.